Literature DB >> 33525639

Subthreshold Nano-Second Laser Treatment and Age-Related Macular Degeneration.

Amy C Cohn1, Zhichao Wu1,2, Andrew I Jobling3, Erica L Fletcher3, Robyn H Guymer1,2.   

Abstract

The presence of drusen is an important hallmark of age-related macular degeneration (AMD). Laser-induced regression of drusen, first observed over four decades ago, has led to much interest in the potential role of lasers in slowing the progression of the disease. In this article, we summarise the key insights from pre-clinical studies into the possible mechanisms of action of various laser interventions that result in beneficial changes in the retinal pigment epithelium/Bruch's membrane/choriocapillaris interface. Key learnings from clinical trials of laser treatment in AMD are also summarised, concentrating on the evolution of laser technology towards short pulse, non-thermal delivery such as the nanosecond laser. The evolution in our understanding of AMD, through advances in multimodal imaging and functional testing, as well as ongoing investigation of key pathological mechanisms, have all helped to set the scene for further well-conducted randomised trials to further explore potential utility of the nanosecond and other subthreshold short pulse lasers in AMD.

Entities:  

Keywords:  age-related macular degeneration; drusen; laser

Year:  2021        PMID: 33525639      PMCID: PMC7866172          DOI: 10.3390/jcm10030484

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  76 in total

1.  Esterified and unesterified cholesterol in drusen and basal deposits of eyes with age-related maculopathy.

Authors:  Christine A Curcio; J Brett Presley; Goldis Malek; Nancy E Medeiros; Dina V Avery; Howard S Kruth
Journal:  Exp Eye Res       Date:  2005-07-11       Impact factor: 3.467

2.  Retinal damage profiles and neuronal effects of laser treatment: comparison of a conventional photocoagulator and a novel 3-nanosecond pulse laser.

Authors:  John P M Wood; O'Sam Shibeeb; Malcolm Plunkett; Robert J Casson; Glyn Chidlow
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-28       Impact factor: 4.799

3.  Treatment of drusen-related aging macular degeneration by photocoagulation.

Authors:  P C Wetzig
Journal:  Trans Am Ophthalmol Soc       Date:  1988

4.  Ranibizumab for neovascular age-related macular degeneration.

Authors:  Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

5.  Abundant lipid and protein components of drusen.

Authors:  Lan Wang; Mark E Clark; David K Crossman; Kyoko Kojima; Jeffrey D Messinger; James A Mobley; Christine A Curcio
Journal:  PLoS One       Date:  2010-04-23       Impact factor: 3.240

6.  Drusen regression is associated with local changes in fundus autofluorescence in intermediate age-related macular degeneration.

Authors:  Brian C Toy; Nupura Krishnadev; Maanasa Indaram; Denise Cunningham; Catherine A Cukras; Emily Y Chew; Wai T Wong
Journal:  Am J Ophthalmol       Date:  2013-07-03       Impact factor: 5.258

7.  Thrombin inhibitor reduces leukocyte-endothelial cell interactions and vascular leakage after scatter laser photocoagulation.

Authors:  Kunihiro Musashi; Junichi Kiryu; Kazuaki Miyamoto; Shinsuke Miyahara; Hideto Katsuta; Hiroshi Tamura; Fumitaka Hirose; Nagahisa Yoshimura
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-07       Impact factor: 4.799

Review 8.  Subthreshold and micropulse diode laser photocoagulation.

Authors:  Giorgio Dorin
Journal:  Semin Ophthalmol       Date:  2003-09       Impact factor: 1.975

9.  Prophylactic laser treatment in early age related maculopathy reduced the incidence of exudative complications.

Authors:  C Frennesson; S E Nilsson
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

10.  Healing of retinal photocoagulation lesions.

Authors:  Yannis M Paulus; Atul Jain; Ray F Gariano; Boris V Stanzel; Michael Marmor; Mark S Blumenkranz; Daniel Palanker
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-29       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.